Parexel launches Health Advances Asia, expanding global footprint with Hong Kong base

Parexel building
CRO Parexel has deepened its presence in the Asia-Pacific region with a new base in Hong Kong. (Parexel)

The so-called Health Advances Asia Limited subsidiary, which forms part of Parexel's consulting unit, is set up to “support development of global expansion strategies for Asia/Pacific and multinational companies from new Hong Kong presence,” according to the firm.

It will be led by biopharma and medtech veteran Gary Cheng, who will be in charge of the local team. Cheng, who counts Novartis, BD, Chiron, Alere and Aventis among his former employers, will also work with Vivek Mittal, a long-time partner at Health Advances in its San Francisco office who will now be based in Hong Kong.

RELATED: Parexel nabs high-profile former FDA staffers, beefing up its regulatory offerings

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“For both local companies in Asia/Pacific and global companies looking to expand into the region, taking advantage of the rapid economic growth in the local healthcare market requires thoughtful and strategic business decisions,” said Paula Ness Speers, Health Advances’ co-founder and managing director.

“Building on our long history of helping companies explore and evaluate opportunities in the Asia/Pacific region and assisting locally-based companies looking to expand beyond their borders, we’re excited to have part of our consulting team now based full-time on the ground in the region to readily support customers in this growing market.”

She continued: “Under Vivek and Gary’s leadership, our local team is well-equipped to help clients across the healthcare sector, including biopharmaceutical, medtech, diagnostics, health IT and digital health, and healthcare services as well as investors in healthcare businesses understand and capitalize on both local and global opportunities.”

Suggested Articles

The FDA has cleared Drawbridge Health’s blood collection device designed to help monitor long-term blood sugar levels in people with diabetes.

Rachel Humphrey, M.D., who joined CytomX as chief medical officer after heading immuno-oncology at AstraZeneca and Eli Lilly, has made her exit.

FierceMedTech Fierce 15 winner 10x Genomics announced its plans for a $100 million IPO, on the Nasdaq using the symbol TXG.